Cardiomyopathy. Cardiomyopathy
Conditions
Interventions
Intervention 1: Intervention group: Rosuvastatin, 20 mg oral pill (by Fanda Pharmaceutical Co.) per day for six months. Intervention 2: Control group: placebo, 20 mg oral pill (by School of Pharmacy,
Treatment - Drugs
Placebo
Intervention group: Rosuvastatin, 20 mg oral pill (by Fanda Pharmaceutical Co.) per day for six months
Control group: placebo, 20 mg oral pill (by School of Pharmacy, Mazandaran University of Medical Sciences) per day for six months
Sponsors
Vice chancellor for research of Mazandaran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Cancerous patients undergoing treatment with anthracycline Exclusion criteria: Patients with history of myocardial infarction; coronary artery disease; patients in the early stages of chemotherapy or radiotherapy; acute restraint or dilated cardiomyopathy; mitral and aortic valvular diseases in initial echocardiography; patients with a history or any symptoms associated with heart failure; hypersensivity to rosuvastatin; active liver diseases; and impaired liver tests; pregnant and lactating women.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Triglycerides level. Timepoint: 0 and 6 month. Method of measurement: mg/dl. | — |
Secondary
| Measure | Time frame |
|---|---|
| Left ventricle ejection fraction. Timepoint: percent. Method of measurement: echocardiography. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactJamil Esmailian
Student Research Committee, Mazandaran University Of Medical Sciences
Outcome results
None listed